BIO-Europe Spring® 2016: Purdue CEO outlines plans for growth away from opioid market

May 12, 2016
During the 2016 BIO-Europe Spring® partnering meeting in Stockholm, Sweden, Mark Timney, president and CEO of Purdue Pharma, caught up with Mike Ward, global director of content for Informa Pharma Intelligence's insights portfolio, to discuss Purdue's big plans for future business outside of opioid therapy. The pair discuss Purdue's five-year plan to build alliances with academic centers and to strike partnerships with industry peers in order to grow and evolve its portfolio to include other pain treatments and novel drugs for central nervous system disorders and other therapy areas. Purdue is not looking to follow in big pharma’s footsteps; Timney tells Ward more about its interest in specified CNS areas, such as epilepsy. He also explains why the company is seeking late-stage deals particularly and what it would take to get his attention at the discovery stage.
Previous Video
BIO-Europe Spring® 2016: Motif's CEO on business leap from discovery to clinical-stage biotech
BIO-Europe Spring® 2016: Motif's CEO on business leap from discovery to clinical-stage biotech

Dr. Graham Lumsden, CEO of London-based biotech Motif Bio, a company focused on the development of therapeu...

Next Video
BIO-Europe Spring® 2016: PILA Pharma CEO explains potential of "chili receptor" as diabetes therapy
BIO-Europe Spring® 2016: PILA Pharma CEO explains potential of "chili receptor" as diabetes therapy

Dr. Dorte Gram, CEO of PILA Pharma AB, one of Sweden's youngest biotech companies, talks to Mike Ward, glob...